Acadia Pharmaceuticals (ACAD) Stock
Small biotech firm developing treatments for brain disorders. Here's the price, business snapshot, and what's worth knowing about Acadia Pharmaceuticals in October 2026.
ACADIA Pharmaceuticals (ACAD) is a clinical-stage biopharmaceutical company focused on disorders of the central nervous system. It is best known for pimavanserin (marketed as Nuplazid in some regions), approved for Parkinson's disease psychosis, and is developing additional indications and programmes in dementia-related psychosis and other neuropsychiatric conditions. Revenue to date has been largely driven by its lead product while the company advances clinical trials and potential label expansions. Investors should be aware that ACADIA’s value is sensitive to binary clinical and regulatory outcomes, patent and exclusivity timelines, and commercial execution. With a market capitalisation around $3.6bn, it sits in the small‑to‑mid cap biotech range and can show higher volatility than large diversified healthcare firms. This summary is for general educational purposes only and not personalised advice; biotech investments carry both upside potential and significant downside risk, and past performance is not indicative of future results.
Acadia Pharmaceuticals (ACAD) Stock Forecast
Analyst price target, next 12 months
$29.15
+48.8% vs today's $19.59
Price range over the last 12 months
Close to its 12-month low
Analysts covering Acadia Pharmaceuticals have a consensus 12-month target of $29.15, above the current price of $19.59.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 7 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ACADIA's stock with a target price of $29.15, indicating growth potential.
Financial Health
ACADIA Pharmaceuticals is generating strong revenue and cash flow, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
CNS-focused pipeline
ACADIA centres on neuropsychiatric and neurodegenerative indications; successful trials could change the investment case, though outcomes are uncertain.
Single-product reliance
Revenue has depended largely on pimavanserin, so commercial performance and patent timelines are key considerations for investors.
Regulatory catalysts ahead
Upcoming trial readouts and regulator decisions can create material share-price moves — both positive and negative — so monitor news and filings closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
